NR3C1 and breast cancer: Our analysis of canonical pathways in IPA suggests that EGCG may reduce breast cancer risk by altering pathways involved in molecular mechanisms of cancer, inflammatory signaling, glucocorticoid receptor signaling, and cytokine signaling.